The addition of an mRNA-based cancer vaccine to pembrolizumab extended RFS among patients with resected high-risk melanoma, according to study results presented at American Association for Cancer Research Annual Meeting.The benefit with the combination persisted regardless of patients’ tumor mutational burden status, findings of the randomized phase 2B KEYNOTE-942 trial showed.
Isaac Perlmutter’s time at Disney had run its course and the former Marvel Entertainment chairman’s removal “was a necessary step in the direction of us…
Isaac Perlmutter’s time at Disney had run its course and the former Marvel Entertainment chairman’s removal “was a necessary step in the direction of us…